Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy

Clinical trial NCT02649387 · COMPLETED

Trial details

NCT number: NCT02649387
Sponsor: Mayo Clinic
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Stage I Chronic Lymphocytic Leukemia Stage II Chronic Lymphocytic Leukemia Stage III Chronic Lymphocytic Leukemia Stage IV Chronic Lymphocytic Leukemia

Start date: 2016-02-08
Primary completion: 2023-12-14
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.